World News Insights
1-3 Minute Gist
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
All Topics Article
Pfizer’s Ploy and the Porous Tax Laws
Keywords:
This NYT editorial says the Pfizer bid to acquire Astra Zeneca is an inversion, a tax maneouvre using openings in U.S. and British tax laws that allows an American company to incorporate in London by acquiring a British company. In effect Pfizer beomes a subsidiary of the British company. This reduces taxes owed even though business takes place at Pfizer as before. NYT says 25 companies have adopted inversions since 2008. The top corporate tax rate in Britain at 20% is lower thant the top rate of 35% in the U.S. Additional tax maoeuvres could make it easier for income shifting to tax havens, and make it possible to free up cash held in foreign countries without the need to first repatriate it to the U.S. The problem is that such maneouvres are taking place at a time of large U.S. deficits, and deep cuts in public services and government investment in R&D, infrastructure, education, that would lead to future economic growth.
Public perceptions of Pfizer's strategies in pursuing the acquisition of Astra-Zeneca- tax avoidance at a time of large government deficits and cuts in public services
05/23/2014
For acquisitions to succeed and be a win-win for both companies there have to be ways in which the productivity of capital can be increased through creative endeavors, new products, and savings, beyond maneouvres around tax laws. An editorial in the NYT makes this point.
Grouped Articles
Pfizer’s Ploy and the Porous Tax Laws
New York Times 05/23/2014
Spurned by AstraZeneca, Pfizer Walks Away
Wall Street Journal 05/27/2014
In Medtronic's Deal for Covidien, an Emphasis on Tax Savings
New York Times 06/16/2014
Medical Merger Part of 'Tax Inversion' Wave
Wall Street Journal 06/17/2014
Why Allergan Is a Cure for What Ails Pfizer
Wall Street Journal 10/30/2015
Apple owes $14.5 billion in back taxes, European authorities say
Washington Post 08/30/2016
Pfizer management.
07/31/2006
Grouped Articles
For Drug Deals, Small Is Beautiful
Wall Street Journal 03/12/2009
In Drug Mergers, There's One Sure Bet: The Layoffs
Wall Street Journal 04/30/2014
Pfizer’s Ploy and the Porous Tax Laws
New York Times 05/23/2014
Spurned by AstraZeneca, Pfizer Walks Away
Wall Street Journal 05/27/2014
Pfizer Bets $15 Billion on New Class of Generic Drugs
New York Times 02/05/2015
Why Allergan Is a Cure for What Ails Pfizer
Wall Street Journal 10/30/2015
Pfizer strategy and restructuring- 2010-2015
04/08/2009
Grouped Articles
Pfizer to Pursue Bid for AstraZeneca
Wall Street Journal 04/28/2014
In Drug Mergers, There's One Sure Bet: The Layoffs
Wall Street Journal 04/30/2014
Pfizer Outlines Post-Wyeth R&D Structure
Wall Street Journal 04/08/2009
Pfizer’s Ploy and the Porous Tax Laws
New York Times 05/23/2014
Spurned by AstraZeneca, Pfizer Walks Away
Wall Street Journal 05/27/2014
Pfizer to Buy Hospira for $16 Billion
Wall Street Journal 02/06/2015
Amy Schulman of Pfizer Nutrition on claiming your voice and spending political capital for women managers
10/12/2013
Grouped Articles
Four Executives on Succeeding in Business as a Woman
New York Times 10/12/2013
Pfizer’s Ploy and the Porous Tax Laws
New York Times 05/23/2014
Executive Women, Finding (and Owning) Their Voice
New York Times 11/13/2014
Engage Girls With Tech Education, Leadership Early, Women CIOs Say
Wall Street Journal 12/04/2014
Sheryl Sandberg: Women Are Leaning In—but They Face Pushback
WSJ 09/27/2016
The real issues at Women20 | Business | DW.COM | 26.04.2017
DW.COM 04/26/2017
Pfizer and the plans for merger with Astra Zeneca in 2014
05/05/2014
Grouped Articles
Pfizer Shouldn't Put Away Its Checkbook
Wall Street Journal 05/05/2014
Pfizer’s Ploy and the Porous Tax Laws
New York Times 05/23/2014
Spurned by AstraZeneca, Pfizer Walks Away
Wall Street Journal 05/27/2014
Pfizer acquisitions and divestments
03/12/2009
Grouped Articles
For Drug Deals, Small Is Beautiful
Wall Street Journal 03/12/2009
Pfizer to Pursue Bid for AstraZeneca
Wall Street Journal 04/28/2014
Pfizer Shouldn't Put Away Its Checkbook
Wall Street Journal 05/05/2014
Pfizer’s Ploy and the Porous Tax Laws
New York Times 05/23/2014
Pfizer to Buy Hospira for $16 Billion
Wall Street Journal 02/06/2015
Pfizer Bets $15 Billion on New Class of Generic Drugs
New York Times 02/05/2015
Pfizer performance 2010-2015
04/19/2011
Grouped Articles
Pfizer’s Ploy and the Porous Tax Laws
New York Times 05/23/2014
Spurned by AstraZeneca, Pfizer Walks Away
Wall Street Journal 05/27/2014
Pfizer to Buy Hospira for $16 Billion
Wall Street Journal 02/06/2015
Pfizer Bets $15 Billion on New Class of Generic Drugs
New York Times 02/05/2015
Why Allergan Is a Cure for What Ails Pfizer
Wall Street Journal 10/30/2015
Wall Street Journal 04/19/2011
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us